Verywell Health on MSN3d
7 Common Causes of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...
Dr. Roach: Hypertension diagnosis hasn't been discussed with patient
Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until ...
The American Journal of Managed Care15h
ZENITH Trial Findings Could Reshape PAH Treatment, Extending Sotatercept’s Reach
Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to ...
The American Journal of Managed Care19h
Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH
Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...
Managed Healthcare Executive16h
Winrevair Shows Promise in Advancing PAH Treatment | ACC 2025
Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...
Fierce Pharma19h
Merck's Winrevair slashes mortality-morbidity risk by 76%
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Healio15h
Trial supports sotatercept as standard of care for high-risk patients with PAH
Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...
MPR14h
Sotatercept Reduces Major Events in High-Risk PAH Patients
Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...
Merck presents results from Phase 3 ZENITH trial of WINREVAIR
Merck (MRK) announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR compared to placebo in adults with ...